Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Novo Nordisk receives Complete Response Letter in the US for faster-acting insulin aspart

Novo Nordisk A/S
Posted on: 07 Oct 16

Bagsværd, Denmark 7 October 2016 - Novo Nordisk today announced that it has received a Complete Response Letter from the US Food and Drug Administration (FDA) regarding the New Drug Application for faster-acting insulin aspart.

In the letter, the FDA requests additional information related to the assay for the immunogenicity and clinical pharmacology data before the review of the New Drug Application can be completed. Novo Nordisk is evaluating the content of the Complete Response Letter and will work closely with the FDA to resolve the outstanding issues.  

"We believe faster-acting insulin aspart can address an unmet medical need for people requiring improved blood glucose control around meals, and our ambitions for this innovative drug are unchanged", says Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "We acknowledge the request for information from FDA and will work closely with the agency to determine the best path forward to complete the review."

The New Drug Application for faster-acting insulin aspart was submitted to the FDA in December 2015. Faster-acting insulin aspart is currently also under review in the EU, Switzerland, Canada, Brazil, South Africa and Argentina.

Further information
Media:   
Katrine Sperling+45 3079 6718 krsp@novonordisk.com
Ken Inchausti (US)+1 609 786 8316 kiau@novonordisk.com
 

Investors:
  
Peter Hugreffe Ankersen+45 3075 9085 phak@novonordisk.com
Melanie Raouzeos+45 3075 3479 mrz@novonordisk.com
Hanna Ögren+45 3079 8519 haoe@novonordisk.com
Kasper Veje (US)+1 609 235 8567  kpvj@novonordisk.com


Company announcement No 69 / 2016

PR161007_FasterActingAspart_CRL_UK


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via GlobeNewswire
HUG#2047717
GlobeNewswire
globenewswire.com

Last updated on: 09/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.